Opiant Pharmaceuticals to Report Fourth Quarter 2020 Financial Results and Host Conference Call and Webcast on March 4, 2021
Opiant Pharmaceuticals (NASDAQ: OPNT) will report its financial results for Q4 and the full year ended December 31, 2020, on March 4, 2021, post-market.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Opiant Pharmaceuticals (NASDAQ: OPNT) will report its financial results for Q4 and the full year ended December 31, 2020, on March 4, 2021, post-market. A conference call is scheduled for the same day at 4:30 p.m. ET, where management will discuss these results. Investors can access the call via phone or webcast on the company’s website. Opiant is known for its development of medications addressing addictions and drug overdose, including the NARCAN® Nasal Spray.
Positive
- Scheduled financial results announcement for Q4 and year-end 2020.
- Management conference call for investor engagement.
Negative
- None.
Details
News Market Reaction – OPNT
The recorded move for OPNT in the trading session of this news was -4.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA MONICA, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the fourth quarter and year ended December 31, 2020, after the financial markets close on Thursday March 4, 2021.
The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday March 4, 2021. To access the call, please dial 877-407-0792 in the U.S. or 201-689-8263 outside the U.S. and provide the conference ID number: 13715395. To access the live webcast, please go to the investors section of Opiant’s website at http://ir.opiant.com/. Following the live webcast, an archived version of the call will be available on the website.
| Thursday March 4 @ 4:30 pm ET | |
| Domestic: | 877-407-0792 |
| International: | 201-689-8263 |
| Conference ID: | 13715395 |
| Webcast: | http://ir.opiant.com/ |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
For more information visit: www.opiant.com.
Investor Relations Contacts:
Ben Atkins
VP of Corporate Communications and Investor Relations
batkins@opiant.com
(310) 598-5410
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.